Tetra Bio-Pharma Inc. today announced the submission of a clinical research application to the Veterinary Drugs Directorate at Health Canada. This first of a kind veterinary study will examine the use of a cannabinoid-based drug to treat ocular pain and inflammation in canines.
Tetra Bio-Pharma Inc. is pleased to announce the promotion of Steeve Néron as Senior Vice President, Marketing and Medical Affairs. The Corporation also announced the conclusion of the dividend-in-kind of North Bud Farms Inc.
Tetra Bio-Pharma Inc. today announced it has entered into a non-binding proposal (the "Proposal") with the shareholders (the "Vendors") of Panag Pharma Inc. ("Panag") for the acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag (the "Proposed Transaction").
Tetra Natural Health Inc. today announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii.
Tetra Bio-Pharma Inc. today announced that is has received a “No Objection Letter” (NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.
Tetra Bio-Pharma Inc. today announced the appointment of Richard Giguère to the position of Chief Executive Officer of Tetra Natural Health Inc. a newly created, wholly owned subsidiary of Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc. today announced the permanent appointment of Guy Chamberland, Ph.D., as CEO and CSO having most recently held the position of CEO in an interim capacity. Dr. Chamberland has more than 23 years' experience in the development of new drugs in the North American pharmaceutical industry.
Tetra Bio-Pharma Inc. today announced it received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for PPP002, its dronabinol AdVersa™ mucoadhesive product.
Tetra Bio-Pharma Inc., in partnership with Ford’s Family Pharmacy and Wellness Center, have developed and implemented a pharmaceutical quality system for Canada’s first botanical-based prescription drug PPP001.
Tetra Bio-Pharma Inc. today announced that it conducted a Type B meeting with the United States Food and Drug Administration (FDA) for its dronabinol AdVersa™ mucoadhesive product, PPP002.